Data on the association of CMPK1 with clinicopathological features and biological effect in human epithelial ovarian cancer

Daibing Zhou; Lingyun Zhang; Qunbo Lin; Weimin Ren; Guoxiong Xu

doi:10.1016/j.dib.2017.05.022

Data on the association of CMPK1 with clinicopathological features and biological effect in human epithelial ovarian cancer

Data Brief. 2017 May 12:13:77-84. doi: 10.1016/j.dib.2017.05.022. eCollection 2017 Aug.

Authors

Daibing Zhou^{1

2}, Lingyun Zhang^{1

2}, Qunbo Lin^{1

2}, Weimin Ren^{1

2}, Guoxiong Xu^{1

2}

Affiliations

¹ Center Laboratory, Jinshan Hospital, Fudan University, Shanghai 201508, China.
² Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Abstract

Human epithelial ovarian cancer (EOC) is the most lethal gynecological disease. However, the molecular mechanisms by which transforming growth factor-β (TGF-β) regulates ovarian tumor progression markers remain unclear. The present data show cytidine monophosphate kinase (CMPK) as an EOC biomarker and are related to the article entitled "Cytidine monophosphate kinase is inhibited by the TGF-β signalling pathway through the upregulation of miR-130b-3p in human epithelial ovarian cancer" [1]. CMPK, as well as cystatin B [2] and β-2-microglobulin [3], is overexpressed in human epithelial-type ovarian tumors. CMPK is an enzyme required for nucleic acid biosynthesis [4] and is regulated by the TGF-β signaling pathway in EOC cells [1]. Furthermore, the data show the effect of CMPK-shRNA on EOC cell apoptosis and TGF-β-induced Smad2 phosphorylation. CMPK expression in two EOC cell lines OVCAR-3 and SK-OV-3 is regulated by multiple miRNAs and some of these miRNAs may affect EOC chemoresistance [5].

Keywords: TGF-β signaling; Therapeutic target; Tissue microarray; Tumorigenesis; UMP/CMP kinase; miRNA.